3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

Dementia and Geriatric Cognitive Disorders
B WinbladR Schindler

Abstract

Delays in the diagnosis of Alzheimer's disease, and, therefore, delays in treatment, may have a detrimental effect on a patient's long-term well-being. This study assessed the effects of postponing donepezil treatment for 1 year by comparing patients treated continuously for 3 years with those who received placebo for 1 year followed by open-label donepezil for 2 years. Patients (n = 286) with possible or probable Alzheimer's disease (according to DSM-IV, NINCDS-ADRDA, and Mini-Mental State Examination criteria; see text) were randomized to receive donepezil (5 mg/day for 4 weeks, 10 mg/day thereafter) or placebo (delayed-start group) for 1 year. Of the 192 completers, 157 began a 2-year, open-label phase of donepezil treatment. Outcome measures were the Gottfries-Bråne-Steen scale, the Mini-Mental State Examination, the Global Deterioration Scale, the Progressive Deterioration Scale, the Neuropsychiatric Inventory, and safety (adverse events). Mixed regression analysis was used to compare changes between the groups over 3 years on the efficacy measures. There was a trend for patients receiving continuous therapy to have less global deterioration (Gottfries-Bråne-Steen scale) than those who had delayed treatment (p = 0.056). Sm...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Feb 1, 1992·The American Journal of Psychiatry·C EisdorferT P Semla
Jul 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·A BurnsR Levy
Oct 1, 1989·Journal of Geriatric Psychiatry and Neurology·S PetryJ Shapira
Jan 1, 1987·Alzheimer Disease and Associated Disorders·A La Rue
Sep 1, 1982·The American Journal of Psychiatry·B ReisbergT Crook
Dec 1, 1982·Archives of Gerontology and Geriatrics·C G GottfriesG Steen
Mar 1, 1997·Archives of General Psychiatry·D P DevanandY Stern
May 15, 1999·Dementia and Geriatric Cognitive Disorders·A BurnsL T Friedhoff
May 4, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S L RogersJ R Ieni
Jun 9, 2000·Statistics in Medicine·R G ThomasL Thal
Jun 9, 2000·Statistics in Medicine·M S MendiondoF A Schmitt
Dec 23, 2000·Dementia and Geriatric Cognitive Disorders·G BråneB Winblad
Aug 15, 2001·Neurology·B WinbladUNKNOWN Donepezil Nordic Study Group
Jul 26, 2002·Psychosomatic Medicine·Elizabeth A BachenStephen B Manuck
Apr 3, 2003·International Psychogeriatrics·Serge GauthierUNKNOWN Donepezil MSAD Study Investigators Group
Jul 2, 2003·Journal of the American Geriatrics Society·David S GeldmacherJohn R Ieni
Sep 28, 2004·International Journal of Geriatric Psychiatry·Kenneth RockwoodIsabelle Lussier
Mar 15, 2005·Alzheimer Disease and Associated Disorders·Howard H FeldmanKoen E L Torfs

❮ Previous
Next ❯

Citations

Mar 16, 2013·Der Nervenarzt·I GroßimlinghausJ Zielasek
Jul 16, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Haruo HanyuKiyoshi Koizumi
Aug 9, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Anders GustavssonLennart Minthon
Oct 29, 2010·The New England Journal of Medicine·Lisa LavelleDiarmuid O'Shea
Jun 19, 2010·The New England Journal of Medicine·Richard Mayeux
Apr 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yukiko YoshidaTsunehiko Ikeda
Jan 16, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G WaldemarUNKNOWN EFNS
Jan 17, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H HanyuT Iwamoto
Jun 10, 2010·International Journal of Clinical Practice·J LindesayT van Laar
Feb 22, 2007·Dementia and Geriatric Cognitive Disorders·Asa K WallinUNKNOWN Swedish Alzheimer Treatment Study Group
Apr 9, 2008·Dementia and Geriatric Cognitive Disorders·Martin R FarlowVojislav Pejovic
Jan 24, 2013·Dementia and Geriatric Cognitive Disorders Extra·Willem J R BossersMarieke J G van Heuvelen
Jul 22, 2011·Alzheimer's Research & Therapy·Carina WattmoLennart Minthon
Mar 15, 2008·Inquiry : a Journal of Medical Care Organization, Provision and Financing·Padmaja AyyagariFrank A Sloan
Apr 8, 2014·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Hugo J Duivenvoorden, Ton Bakker
Aug 15, 2014·Journal of Natural Medicines·Kazuya MurataHideaki Matsuda
Oct 5, 2013·Current Translational Geriatrics and Experimental Gerontology Reports·Lawrence S Honig, Clara D Boyd
Sep 8, 2010·The Journal of Nutrition, Health & Aging·P Martinez-LageK Berthet
Sep 8, 2010·The Journal of Nutrition, Health & Aging·F ForetteS Knox
Sep 13, 2008·Scandinavian Journal of Primary Health Care·Erik JedeniusNiels Andreasen
Feb 27, 2009·Expert Opinion on Investigational Drugs·Laurent LecanuVassilios Papadopoulos
May 3, 2014·Expert Opinion on Drug Metabolism & Toxicology·David Prvulovic, Barbara Schneider
May 3, 2007·Expert Opinion on Pharmacotherapy·Ben Seltzer
Oct 22, 2013·Clinical Therapeutics·Haakon B Nygaard
Oct 18, 2016·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Gary W Small
Sep 5, 2014·Alzheimer Disease and Associated Disorders·Joel C MitchellRaphael Ziegler
Oct 25, 2006·Journal of Psychopharmacology·Alistair BurnsUNKNOWN British Association for Psychopharmacology
Dec 3, 2008·American Journal of Alzheimer's Disease and Other Dementias·Magda TsolakiSofia Karamavrou
Feb 28, 2009·American Journal of Alzheimer's Disease and Other Dementias·Bengt Winblad
May 22, 2013·American Journal of Alzheimer's Disease and Other Dementias·Carina Wattmo
Jul 6, 2017·Expert Opinion on Drug Safety·Dana MohammadNathan Herrmann
Jan 31, 2012·Dementia and Geriatric Cognitive Disorders·Ton J E M BakkerMiel W Ribbe
Nov 7, 2015·Journal of Telemedicine and Telecare·Heeseok KimJae-Won Jang
Sep 18, 2018·The New England Journal of Medicine·John J McNeilUNKNOWN ASPREE Investigator Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.